Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - rinnanäärmed - antineoplastilised ained - talzenna on näidustatud monotherapy raviks täiskasvanud patsientidel, kellel germline brca1/2 mutatsioonid, kes on her2-negatiivse lokaalselt kaugelearenenud või metastaatilise rinnavähi. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patsiendid, kellel on hormooni retseptori (hr)-positiivse rinnavähi peaks olema töödeldud enne sisesekretsioonisüsteemi põhinev ravi, või pidada sobi sisesekretsiooni-põhine ravi.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

celgene europe bv - asatsitidiin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastilised ained - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - hematopoeetiline tüvirakkude siirdamine - antineoplastilised ained - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - Ühenduse omandatud infektsioonid - antibacterials süsteemseks kasutamiseks, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Εσθονία - Εσθονικά - Ravimiamet

interchemie werken de adelaar eesti aktsiaselts - florfenikool - süstelahus - 300mg 1ml 100ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

intervet international b.v. - sigade inaktiveeritud parvoviirusvaktsiin+leptospira inaktiveeritud vaktsiin+erysipelothrix rhusiopathiae, inaktiveeritud - süstesuspensioon - 1annus+1annus+1annus 2ml 50ml 1tk; 1annus+1annus+1annus 2ml 20ml 1tk; 1annus+1annus+1annus 2ml 250ml 1tk; 1annus+1annus+1annus 2ml 20ml 10tk; 1annus+1annus+1annus 2ml 100ml 1tk; 1annus+1annus+1annus 2ml 50ml 10tk

Εσθονία - Εσθονικά - Ravimiamet

livisto int'l s.l. - florfenikool - süstelahus - 300mg 1ml 250ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

intervet international b.v. - florfenikool+fluniksiin - süstelahus - 300mg+16,5mg 1ml 100ml 1tk; 300mg+16,5mg 1ml 250ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

eurovet animal health b.v. - sulfametoksasool+trimetoprim - lahus joogivees manustamiseks - 100mg+20mg 1ml 5000ml 1tk; 100mg+20mg 1ml 1000ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

interchemie werken de adelaar eesti aktsiaselts - ksülasiin - süstelahus - 20mg 1ml 50ml 5tk